Johnson & Johnson JNJ
NYSE JNJ
$269.99 -0.22 (-0.08%)
At close: Sep 18, 2026 · 4:00 PM EDT

Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Other Non-Current Assets came in at $14.3 billion in Q2 2026, up 17.06% year-over-year from $12.2 billion in Q2 2025, and up 1.16% quarter-over-quarter from $14.1 billion in Q1 2026.

Analysis

Johnson & Johnson (JNJ) Other Non-Current Assets (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $14.3 billion for Q2 2026.

  • In Q2 2026, Other Non-Current Assets rose 17.06% year-over-year to $14.3 billion; the TTM figure through Jun 2026 stood at $14.3 billion (up 17.06% YoY), while the FY2025 annual figure was $14.4 billion, up 25.88% from the prior year.
  • Other Non-Current Assets came in at $14.3 billion for Q2 2026 at Johnson & Johnson, up from $14.1 billion in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $27.2 billion in Q1 2023 to a low of $8.6 billion in Q4 2022.
  • Average Other Non-Current Assets over 5 years is $12.5 billion, with a median of $11.5 billion recorded in 2025.
  • The largest YoY upside for Other Non-Current Assets was 166.61% in 2023 against a maximum downside of 48.04% in 2023.
  • Over 5 years, Other Non-Current Assets stood at $8.6 billion in 2022, then surged by 64.09% to $14.2 billion in 2023, then fell by 19.35% to $11.4 billion in 2024, then grew by 25.88% to $14.4 billion in 2025, then slipped by 0.69% to $14.3 billion in 2026.
  • Per Business Quant data, the three most recent Other Non-Current Assets figures were $14.3 billion in Q2 2026, $14.1 billion in Q1 2026, and $14.4 billion in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Johnson & Johnson 650.65 Bn 629.89 Bn 17.26 Bn 14.27 Bn
2 AbbVie 466.34 Bn 459.82 Bn 12.70 Bn 10.73 Bn
3 Merck 362.11 Bn 355.02 Bn 12.21 Bn 19.60 Bn
4 Novartis Ag 267.81 Bn 260.52 Bn 11.24 Bn 5.93 Bn
5 Pfizer 157.31 Bn 145.91 Bn 10.94 Bn 9.94 Bn
6 Bristol Myers Squibb 128.75 Bn 117.69 Bn 9.25 Bn 6.38 Bn
7 Sanofi 51.80 Bn 44.84 Bn 10.79 Bn 5.50 Bn
8 Revolution Medicines 40.91 Bn 40.91 Bn - 42.45 Mn
9 BeOne Medicines 39.65 Bn 34.55 Bn 1.53 Bn 109.58 Mn
10 Incyte 25.18 Bn 20.65 Bn 1.57 Bn 86.76 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 28, 2026 14.27 Bn
Mar 29, 2026 14.11 Bn
Dec 28, 2025 14.37 Bn
Sep 28, 2025 12.42 Bn
Jun 29, 2025 12.19 Bn
Mar 30, 2025 11.53 Bn
Dec 29, 2024 11.41 Bn
Sep 29, 2024 10.92 Bn
Jun 30, 2024 10.54 Bn
Mar 31, 2024 14.13 Bn
Dec 31, 2023 14.15 Bn
Oct 1, 2023 13.13 Bn
Jul 2, 2023 10.08 Bn
Apr 2, 2023 9.57 Bn
Jan 1, 2023 27.24 Bn
Oct 2, 2022 8.63 Bn
Jul 3, 2022 9.44 Bn
Apr 3, 2022 9.94 Bn
Jan 2, 2022 10.22 Bn
Oct 3, 2021 6.87 Bn